Literature DB >> 8613010

Sex steroid metabolism and receptor status in hepatic hyperplasia and cancer in rats.

P K Eagon1, M S Elm, M J Epley, H Shinozuka, K N Rao.   

Abstract

BACKGROUND & AIMS: Both androgenic and estrogenic steroids have been implicated in the development and course of several liver diseases, including hepatocellular carcinoma. The aim of this study was to investigate temporal changes in hepatic estrogen and androgen receptors and hormone metabolism in a rat model of liver hyperplasia and carcinogenesis.
METHODS: Rats were fed hepatocarcinogenic peroxisome proliferator agents for 3 days to 10 months. Livers were examined for proliferation markers, activity and cellular distribution of sex steroid receptors, and key enzymes in sex hormone homeostasis.
RESULTS: At all times, liver weight and proliferation markers in treated rats were increased. Early exposure resulted in increased nuclear estrogen and androgen receptor activity in treated rats. Tumors that developed after 9-10 months showed a marked decrease in estrogen receptor activity and, in contrast, an increase in androgen receptor activity, as did liver surrounding the tumors. Both short-term and long-term exposure to the carcinogens resulted in dramatic reductions in steroid metabolism.
CONCLUSIONS: This study supports the thesis that, in preneoplastic stages such as hyperplasia, there is an elevation of both receptor activities and that the progression from hyperplasia to cancer results in suppression of estrogen receptor expression but maintenance of androgen receptor.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8613010     DOI: 10.1053/gast.1996.v110.pm8613010

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  8 in total

Review 1.  Role of sex steroid receptors in pathobiology of hepatocellular carcinoma.

Authors:  Mamta Kalra; Jary Mayes; Senait Assefa; Anil-K Kaul; Rashmi Kaul
Journal:  World J Gastroenterol       Date:  2008-10-21       Impact factor: 5.742

2.  Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma.

Authors:  Wen-Lung Ma; Cheng-Lung Ma; Cheng-Lung Hsu; Ming-Heng Wu; Chun-Te Wu; Cheng-Chia Wu; Jiann-Jyh Lai; Yuh-Shan Jou; Chun-Wei Chen; Shuyuan Yeh; Chawnshang Chang
Journal:  Gastroenterology       Date:  2008-05-22       Impact factor: 22.682

Review 3.  Women and primary biliary cirrhosis.

Authors:  Ying Sun; Krista Haapanen; Baosen Li; Weici Zhang; Judy Van de Water; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

4.  Liver expression of steroid hormones and Apolipoprotein D receptors in hepatocellular carcinoma.

Authors:  F J Vizoso; M Rodriguez; A Altadill; M L González-Diéguez; A Linares; L O González; S Junquera; F Fresno-Forcelledo; M D Corte; L Rodrigo
Journal:  World J Gastroenterol       Date:  2007-06-21       Impact factor: 5.742

Review 5.  Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway?

Authors:  Mahmoud A Ali; Sahin Lacin; Reham Abdel-Wahab; Mark Uemura; Manal Hassan; Asif Rashid; Dan G Duda; Ahmed O Kaseb
Journal:  Onco Targets Ther       Date:  2017-03-03       Impact factor: 4.147

6.  Sex hormone dependency of diethylnitrosamine-induced liver tumors in mice and chemoprevention by leuprorelin.

Authors:  T Nakatani; G Roy; N Fujimoto; T Asahara; A Ito
Journal:  Jpn J Cancer Res       Date:  2001-03

7.  Liver-specific androgen receptor knockout attenuates early liver tumor development in zebrafish.

Authors:  Hankun Li; Yan Li; Jeng-Wei Lu; Xiaojing Huo; Zhiyuan Gong
Journal:  Sci Rep       Date:  2019-07-23       Impact factor: 4.379

8.  Computational modeling identifies key gene regulatory interactions underlying phenobarbital-mediated tumor promotion.

Authors:  Raphaëlle Luisier; Elif B Unterberger; Jay I Goodman; Michael Schwarz; Jonathan Moggs; Rémi Terranova; Erik van Nimwegen
Journal:  Nucleic Acids Res       Date:  2014-01-23       Impact factor: 16.971

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.